Literature DB >> 30583712

A 24-hour perioperative case study on argatroban use for left ventricle assist device insertion during cardiopulmonary bypass and veno-arterial extracorporeal membrane oxygenation.

Philip Fernandes1, Michael O'Neil1, Samantha Del Valle1, Anita Cave2, Dave Nagpal3,4.   

Abstract

A 44-year-old male with ongoing chest pain and left ventricular ejection fraction <20% was transferred from a peripheral hospital with intra-aortic balloon pump placement following a non-ST-elevation myocardial infarction (STEMI). The patient underwent emergent multi-vessel coronary artery bypass grafting requiring veno-arterial (VA) extracorporeal membrane oxygenation (ECMO) on post-operative day (POD)#9 secondary to cardiogenic shock with biventricular failure. Due to clot formation, an oxygenator change-out was necessary shortly after initiation. Following a positive heparin-induced thrombocytopenia (HIT) assay, a total circuit exchange was required to eliminate all heparin coating and argatroban was deemed the anticoagulant of choice due to acute kidney injury. On POD#24, the decision was made to implant a left ventricle assist device (LVAD) as a bridge to heart transplantation. There was difficulty achieving an activated clotting time (ACT) >400 s: multiple argatroban bolus doses were required, along with accelerated up-titration of infusion dosing. Despite maintaining an ACT >484 s, clot formation was observed in the cardiotomy reservoir prior to separation. Subsequently, the patient developed severe disseminated intravascular coagulopathy, with both intra-cardiac and intravascular thrombi, requiring massive transfusion and continuous cell saving due to severe hemorrhage post cardiopulmonary bypass (CPB). The patient received a total of 105 units of plasma, 74 units of packed red cells, 19 units of platelets, 13 bottles of 5% albumin, 6 units of cryoprecipitate and 2 doses of factor VIIa intraoperatively over the course of 24 hours. A total of 19.7 L of washed red blood cells were returned to the patient from the cell saver. With the LVAD in place, the patient developed transfusion-related acute lung injury and acute respiratory distress syndrome with right ventricular dysfunction requiring VA ECMO once again. On POD#30, ECMO was discontinued and the patient was discharged from the intensive care unit (ICU) on POD 66. After a very complex post-operative stay with numerous surgeries and extensive rehabilitation, the patient was discharged home with the LVAD on POD#112.

Entities:  

Keywords:  CPB; ECMO; LVAD; argatroban; dosing

Year:  2018        PMID: 30583712     DOI: 10.1177/0267659118813043

Source DB:  PubMed          Journal:  Perfusion        ISSN: 0267-6591            Impact factor:   1.972


  3 in total

1.  Therapeutic Anticoagulation with Argatroban and Heparins Reduces Granulocyte Migration: Possible Impact on ECLS-Therapy?

Authors:  Andre Bredthauer; Manuel Kopfmueller; Michael Gruber; Sophie-Marie Pfaehler; Karla Lehle; Walter Petermichl; Timo Seyfried; Diane Bitzinger; Andreas Redel
Journal:  Cardiovasc Ther       Date:  2020-04-25       Impact factor: 3.023

2.  Management of heparin-induced thrombocytopenia: systematic reviews and meta-analyses.

Authors:  Rebecca L Morgan; Vahid Ashoorion; Adam Cuker; Housne Begum; Stephanie Ross; Nina Martinez; Beng H Chong; Lori A Linkins; Theodore E Warkentin; Wojtek Wiercioch; Robby Nieuwlaat; Holger Schünemann; Nancy Santesso
Journal:  Blood Adv       Date:  2020-10-27

Review 3.  Anticoagulation with direct thrombin inhibitors during extracorporeal membrane oxygenation.

Authors:  Barry Burstein; Patrick M Wieruszewski; Yan-Jun Zhao; Nathan Smischney
Journal:  World J Crit Care Med       Date:  2019-10-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.